Alpha-Mannosidosis Clinical Trial
Official title:
A Multi-center, Un-controlled, Open-labeled Trial of the Long-term Safety of Lamazym Aftercare Treatment of Subjects With Alpha-Mannosidosis Whom Previously Participated in Lamazym Trials
The overall objective of this trial is to provide aftercare treatment with Lamazym and to evaluate the safety of repeated Lamzede i.v. treatment of subjects with alpha-Mannosidosis.
This trial provide aftercare treatment with Lamzede to French patients. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02254863 -
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
|
Phase 1 | |
Not yet recruiting |
NCT06184503 -
Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3
|
||
Completed |
NCT01908725 -
Lamazym Aftercare Study
|
Phase 3 | |
Completed |
NCT02141503 -
Clinical Biomarkers in Alpha-mannosidosis
|
||
Recruiting |
NCT02171104 -
MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis
|
Phase 2 | |
Completed |
NCT01681940 -
Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis
|
Phase 2 | |
Withdrawn |
NCT04031066 -
Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis
|
Phase 3 | |
Recruiting |
NCT03333200 -
Longitudinal Study of Neurodegenerative Disorders
|
||
Completed |
NCT02478840 -
Evaluation of Long-term Efficacy of Treatment With Lamazym
|
Phase 3 | |
Completed |
NCT02998879 -
Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis
|
Phase 2 | |
Completed |
NCT01681953 -
A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis
|
Phase 3 | |
Terminated |
NCT01372228 -
Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders
|
Phase 1/Phase 2 | |
Available |
NCT04959240 -
Expanded Access to Velmanase Alfa
|